TransMedics Group (NASDAQ:TMDX) Stock Price Up 7.4% – What’s Next?

TransMedics Group, Inc. (NASDAQ:TMDX) rose 7.4% on Monday . The company traded as high as $86.60 and last traded at $86.54. Approximately 907,876 shares changed hands during trading, a decline of 32% from the average daily volume of 1,332,665 shares. The stock had previously closed at $80.58.

Analysts Set New Price Targets

Several analysts recently weighed in on the company. Needham & Company LLC restated a “hold” rating on shares of TransMedics Group in a report on Wednesday, March 26th. JPMorgan Chase & Co. restated a “neutral” rating and issued a $75.00 price target (down previously from $116.00) on shares of TransMedics Group in a report on Tuesday, December 17th. Finally, Canaccord Genuity Group reiterated a “buy” rating and set a $104.00 price objective on shares of TransMedics Group in a research note on Tuesday, March 11th. Three equities research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $122.70.

TransMedics Group Stock Up 0.4 %

The company has a market capitalization of $2.93 billion, a price-to-earnings ratio of 92.75 and a beta of 2.14. The company has a debt-to-equity ratio of 2.42, a quick ratio of 7.33 and a current ratio of 8.20. The business’s 50 day moving average is $71.46 and its 200 day moving average is $80.72.

Hedge Funds Weigh In On TransMedics Group

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. NBC Securities Inc. purchased a new position in shares of TransMedics Group in the first quarter worth about $25,000. Atlas Capital Advisors Inc. purchased a new position in TransMedics Group during the 4th quarter worth approximately $31,000. Hager Investment Management Services LLC acquired a new stake in TransMedics Group during the 4th quarter valued at approximately $33,000. Sachetta LLC purchased a new stake in shares of TransMedics Group in the 4th quarter valued at $40,000. Finally, AlphaQuest LLC acquired a new stake in shares of TransMedics Group in the fourth quarter worth $52,000. Hedge funds and other institutional investors own 99.67% of the company’s stock.

About TransMedics Group

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.